On the public citation graph

A Comprehensive Overview of Protacs Targeting Hsp90 and Their Client Proteins for Cancer Therapy

https://doi.org/10.2139/ssrn.5125761
0 signed · 105 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/anie.201507978openalex-snapshot
Small‐Molecule PROTACS: New Approaches to Protein Degradation
inferredcites →https://doi.org/10.1002/cbic.202100270openalex-snapshot
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
inferredcites →https://doi.org/10.1002/ijc.29682openalex-snapshot
Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies
inferredcites →https://doi.org/10.1002/ijc.34671openalex-snapshot
Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study
inferredcites →https://doi.org/10.1002/mco2.470openalex-snapshot
Heat shock protein 90: biological functions, diseases, and therapeutic targets
inferredcites →https://doi.org/10.1007/s00134-019-05650-wopenalex-snapshot
Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases
inferredcites →https://doi.org/10.1007/s10495-010-0466-zopenalex-snapshot
Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications
inferredcites →https://doi.org/10.1007/s12035-024-04284-4openalex-snapshot
The Role of HSP90 Molecular Chaperones in Depression: Potential Mechanisms
inferredcites →https://doi.org/10.1016/b978-0-08-046884-6.01402-0openalex-snapshot
Multistage Carcinogenesis: Cell and Animal Models
inferredcites →https://doi.org/10.1016/b978-0-12-801238-3.02218-2openalex-snapshot
Multistage Carcinogenesis: Cell and Animal Models
inferredcites →https://doi.org/10.1016/j.apsb.2023.09.003openalex-snapshot
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
inferredcites →https://doi.org/10.1016/j.bbamcr.2011.09.003openalex-snapshot
The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones
inferredcites →https://doi.org/10.1016/j.breast.2012.04.002openalex-snapshot
Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?
inferredcites →https://doi.org/10.1016/j.cclet.2022.107927openalex-snapshot
Current strategies for improving limitations of proteolysis targeting chimeras
inferredcites →https://doi.org/10.1016/j.cell.2006.09.027openalex-snapshot
Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements
inferredcites →https://doi.org/10.1016/j.cell.2019.11.031openalex-snapshot
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
inferredcites →https://doi.org/10.1016/j.chembiol.2020.07.020openalex-snapshot
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
inferredcites →https://doi.org/10.1016/j.chembiol.2021.02.024openalex-snapshot
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
inferredcites →https://doi.org/10.1016/j.cstres.2024.05.005openalex-snapshot
An update on the status of HSP90 inhibitors in cancer clinical trials
inferredcites →https://doi.org/10.1016/j.cytogfr.2008.08.006openalex-snapshot
The many faces of the SOCS box
inferredcites →https://doi.org/10.1016/j.ebiom.2018.09.005openalex-snapshot
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
inferredcites →https://doi.org/10.1016/j.ejmech.2020.112993openalex-snapshot
PROTACs to address the challenges facing small molecule inhibitors
inferredcites →https://doi.org/10.1016/j.ejmech.2021.114013openalex-snapshot
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer
inferredcites →https://doi.org/10.1016/j.ejmech.2023.115690openalex-snapshot
Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer
inferredcites →https://doi.org/10.1016/j.ejmech.2023.115911openalex-snapshot
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
inferredcites →https://doi.org/10.1016/j.ejmech.2023.116096openalex-snapshot
Progress in the controllability technology of PROTAC
inferredcites →https://doi.org/10.1016/j.ejmech.2024.116166openalex-snapshot
Annual review of PROTAC degraders as anticancer agents in 2022
inferredcites →https://doi.org/10.1016/j.ejmech.2024.116572openalex-snapshot
Novel Hsp90-Targeting PROTACs: Enhanced synergy with cisplatin in combination therapy of cervical cancer
inferredcites →https://doi.org/10.1016/j.ejmech.2024.116725openalex-snapshot
PROTAC technology: From drug development to probe technology for target deconvolution
inferredcites →https://doi.org/10.1016/j.ejps.2023.106624openalex-snapshot
Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment
inferredcites →https://doi.org/10.1016/j.freeradbiomed.2018.09.014openalex-snapshot
Role of GPX4 in ferroptosis and its pharmacological implication
inferredcites →https://doi.org/10.1016/j.mce.2019.110452openalex-snapshot
Targeting Nuclear Receptors with PROTAC degraders
inferredcites →https://doi.org/10.1016/j.medp.2023.100004openalex-snapshot
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
inferredcites →https://doi.org/10.1016/j.molstruc.2023.137266openalex-snapshot
Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors
inferredcites →https://doi.org/10.1021/acs.biochem.2c00245openalex-snapshot
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
inferredcites →https://doi.org/10.1021/acs.chemrev.2c00915openalex-snapshot
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01774openalex-snapshot
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
inferredcites →https://doi.org/10.1021/acs.jmedchem.2c01648openalex-snapshot
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
inferredcites →https://doi.org/10.1021/acs.jmedchem.3c00736openalex-snapshot
Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation
inferredcites →https://doi.org/10.1021/acs.jmedchem.4c01518openalex-snapshot
Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis
inferredcites →https://doi.org/10.1021/acs.jmedchem.8b00378openalex-snapshot
New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm
inferredcites →https://doi.org/10.1021/acsmedchemlett.9b00584openalex-snapshot
PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics
inferredcites →https://doi.org/10.1021/acsmedchemlett.9b00597openalex-snapshot
PROTAC Technology: Opportunities and Challenges
inferredcites →https://doi.org/10.1021/cb600224wopenalex-snapshot
Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive
inferredcites →https://doi.org/10.1038/cr.2013.169openalex-snapshot
Historical landmarks of autophagy research
inferredcites →https://doi.org/10.1038/ja.2011.60openalex-snapshot
Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
inferredcites →https://doi.org/10.1038/nrd.2016.211openalex-snapshot
Induced protein degradation: an emerging drug discovery paradigm
inferredcites →https://doi.org/10.1038/nrd892openalex-snapshot
The druggable genome
inferredcites →https://doi.org/10.1038/nrm2918openalex-snapshot
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
inferredcites →https://doi.org/10.1038/onc.2014.291openalex-snapshot
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
inferredcites →https://doi.org/10.1038/s41419-020-2298-2openalex-snapshot
Ferroptosis: past, present and future
inferredcites →https://doi.org/10.1038/s41523-022-00493-zopenalex-snapshot
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
inferredcites →https://doi.org/10.1038/s41568-021-00365-xopenalex-snapshot
Advancing targeted protein degradation for cancer therapy
inferredcites →https://doi.org/10.1038/s41589-021-00878-4openalex-snapshot
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
inferredcites →https://doi.org/10.1038/s41594-024-01337-zopenalex-snapshot
Structural basis for the dynamic chaperoning of disordered clients by Hsp90
inferredcites →https://doi.org/10.1038/sj.emboj.7600141openalex-snapshot
Erratum: Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery
inferredcites →https://doi.org/10.1039/d2cb00207hopenalex-snapshot
Protein–protein interfaces in molecular glue-induced ternary complexes: classification, characterization, and prediction
inferredcites →https://doi.org/10.1039/d2cs00193dopenalex-snapshot
PROTACs: past, present and future
inferredcites →https://doi.org/10.1039/d2cs00197gopenalex-snapshot
Chasing molecular glue degraders: screening approaches
inferredcites →https://doi.org/10.1039/d2md00273fopenalex-snapshot
Targeted protein degradation using the lysosomal pathway
inferredcites →https://doi.org/10.1073/pnas.141230798openalex-snapshot
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
inferredcites →https://doi.org/10.1073/pnas.1414073111openalex-snapshot
The charged linker of the molecular chaperone Hsp90 modulates domain contacts and biological function
inferredcites →https://doi.org/10.1074/jbc.m103773200openalex-snapshot
Stoichiometry, Abundance, and Functional Significance of the hsp90/hsp70-based Multiprotein Chaperone Machinery in Reticulocyte Lysate
inferredcites →https://doi.org/10.1080/1061186x.2023.2185247openalex-snapshot
Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo
inferredcites →https://doi.org/10.1080/14756366.2023.2254012openalex-snapshot
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
inferredcites →https://doi.org/10.1080/15548627.2022.2091338openalex-snapshot
Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)
inferredcites →https://doi.org/10.1080/17460441.2024.2360416openalex-snapshot
Hydrophobic tagging of small molecules: an overview of the literature and future outlook
inferredcites →https://doi.org/10.1093/abbs/gmaa053openalex-snapshot
The application of ubiquitin ligases in the PROTAC drug design
inferredcites →https://doi.org/10.1093/nar/gkaa807openalex-snapshot
PROTAC-DB: an online database of PROTACs
inferredcites →https://doi.org/10.1111/bph.15014openalex-snapshot
Proteolysis‐targeting chimeras in drug development: A safety perspective
inferredcites →https://doi.org/10.1111/bph.16079openalex-snapshot
The application of targeted protein degradation technologies to G protein‐coupled receptors
inferredcites →https://doi.org/10.1126/science.aam7340openalex-snapshot
Waste disposal—An attractive strategy for cancer therapy
inferredcites →https://doi.org/10.1146/annurev-pharmtox-022123-104147openalex-snapshot
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
inferredcites →https://doi.org/10.1146/annurev.ge.22.120188.003215openalex-snapshot
THE HEAT-SHOCK PROTEINS
inferredcites →https://doi.org/10.1186/1471-2407-10-294openalex-snapshot
Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation
inferredcites →https://doi.org/10.1186/s12885-021-07946-xopenalex-snapshot
Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China
inferredcites →https://doi.org/10.1186/s12916-022-02287-3openalex-snapshot
Targeted therapies for cancer
inferredcites →https://doi.org/10.1186/s43046-021-00088-yopenalex-snapshot
Reviewing cancer’s biology: an eclectic approach
inferredcites →https://doi.org/10.1186/s43556-022-00112-0openalex-snapshot
An overview of PROTACs: a promising drug discovery paradigm
inferredcites →https://doi.org/10.1200/jco.2019.37.7_suppl.259openalex-snapshot
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
inferredcites →https://doi.org/10.1200/jco.2022.40.16_suppl.tps3171openalex-snapshot
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.
inferredcites →https://doi.org/10.1200/jco.2022.40.16_suppl.tps7581openalex-snapshot
A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.
inferredcites →https://doi.org/10.1200/jco.2023.41.16_suppl.tps3163openalex-snapshot
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.
inferredcites →https://doi.org/10.1200/jco.2024.42.4_suppl.134openalex-snapshot
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
inferredcites →https://doi.org/10.1212/wnl.0000000000001860openalex-snapshot
The autophagy-lysosomal pathway
inferredcites →https://doi.org/10.1242/jcs.114.11.2015openalex-snapshot
The Drosophila Dpit47 protein is a nuclear Hsp90 co-chaperone that interacts with DNA polymerase α
inferredcites →https://doi.org/10.1634/theoncologist.7-6-477openalex-snapshot
FDA Drug Approval Summaries: Fulvestrant
inferredcites →https://doi.org/10.2174/138161213804143617openalex-snapshot
Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development
inferredcites →https://doi.org/10.2174/1389450116666150518102831openalex-snapshot
Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?
inferredcites →https://doi.org/10.2183/pjab.85.12openalex-snapshot
The proteasome: Overview of structure and functions
inferredcites →https://doi.org/10.31674/ijbb.2024.v01i01.001openalex-snapshot
A Short Review on Breast Cancer
inferredcites →https://doi.org/10.3322/caac.21834openalex-snapshot
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3389/fchem.2023.1219883openalex-snapshot
Development of the first geldanamycin-based HSP90 degraders
inferredcites →https://doi.org/10.3389/fonc.2023.1122508openalex-snapshot
Targeted therapies for the treatment of soft tissue sarcoma
inferredcites →https://doi.org/10.3389/fonc.2023.1123464openalex-snapshot
Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma
inferredcites →https://doi.org/10.3389/fonc.2023.1196005openalex-snapshot
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
inferredcites →https://doi.org/10.3390/biology13090716openalex-snapshot
Extracellular Vesicles: Diagnostic and Therapeutic Applications in Cancer
inferredcites →https://doi.org/10.3390/cancers6021065openalex-snapshot
The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
inferredcites →https://doi.org/10.3390/cells11060976openalex-snapshot
Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches
inferredcites →https://doi.org/10.3390/ijms19092560openalex-snapshot
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
inferredcites →https://doi.org/10.3390/ijms25105468openalex-snapshot
Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review
inferredcites →https://doi.org/10.3390/ijms25105489openalex-snapshot
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
inferredcites →https://doi.org/10.3390/ph13050095openalex-snapshot
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
inferredcites →https://doi.org/10.3390/pharmaceutics15102442openalex-snapshot
TACkling Cancer by Targeting Selective Protein Degradation
inferredcites →https://doi.org/10.4155/tde-2017-0054openalex-snapshot
An Industry update: the Latest Developments in the Field of Therapeutic Delivery
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.